Esmolol: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
|||
| Line 9: | Line 9: | ||
==Overview== | ==Overview== | ||
'''Esmolol''' (trade name '''Brevibloc''') is a cardioselective [[beta-blocker|beta<sub>1</sub> receptor blocker]] with rapid onset,<ref name="pmid17235414">{{cite journal |author=Deng CY |title=Esmolol inhibits Na+ current in rat ventricular myocytes |journal=Methods Find Exp Clin Pharmacol |volume=28 |issue=10 |pages=697–702 |date=December 2006 |pmid=17235414 |doi=10.1358/mf.2006.28.10.1037498 |url=http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=6&p_RefId=1037498 |author-separator=, |author2=Lin SG |author3=Zhang WC |display-authors=3 |last4=Kuang |first4=S.J. |last5=Qian |first5=W.M. |last6=Wu |first6=S.L. |last7=Shan |first7=Z.X. |last8=Yang |first8=M. |last9=Yu |first9=X.Y.}}</ref> a very short duration of action, and no significant intrinsic [[sympathomimetic]] or membrane stabilising activity at therapeutic dosages. | |||
It is a class II [[antiarrhythmic]].<ref name="pmid2688391">{{cite journal |author=Jaillon P, Drici M |title=Recent antiarrhythmic drugs |journal=Am. J. Cardiol. |volume=64 |issue=20 |pages=65J–69J |date=December 1989 |pmid=2688391 |doi= 10.1016/0002-9149(89)91203-4|url=}}</ref> | |||
Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the [[sympathetic nervous system]], which are found in the [[heart]] and other organs of the body. Esmolol prevents the action of two naturally occurring substances: [[epinephrine]] and [[norepinephrine]] | |||
==Category== | ==Category== | ||
Revision as of 17:47, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names: BREVIBLOC®
Overview
Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset,[1] a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilising activity at therapeutic dosages.
It is a class II antiarrhythmic.[2]
Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic receptors of the sympathetic nervous system, which are found in the heart and other organs of the body. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine
Category
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ Deng CY; Lin SG; Zhang WC; et al. (December 2006). "Esmolol inhibits Na+ current in rat ventricular myocytes". Methods Find Exp Clin Pharmacol. 28 (10): 697–702. doi:10.1358/mf.2006.28.10.1037498. PMID 17235414. Unknown parameter
|author-separator=ignored (help) - ↑ Jaillon P, Drici M (December 1989). "Recent antiarrhythmic drugs". Am. J. Cardiol. 64 (20): 65J–69J. doi:10.1016/0002-9149(89)91203-4. PMID 2688391.